Kümmerle-Deschner, J., Ramos, E., Blank, N., Roesler, J., Felix, S. D., Jung, T., . . . Rordorf, C. (2011). Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Research & Therapy, 13, . https://doi.org/10.1186/ar3266
Chicago-Zitierstil (17. Ausg.)Kümmerle-Deschner, Jasmin, et al. "Canakinumab (ACZ885, a Fully Human IgG1 Anti-IL-1β MAb) Induces Sustained Remission in Pediatric Patients with Cryopyrin-associated Periodic Syndrome (CAPS)." Arthritis Research & Therapy 13 (2011). https://doi.org/10.1186/ar3266.
MLA-Zitierstil (9. Ausg.)Kümmerle-Deschner, Jasmin, et al. "Canakinumab (ACZ885, a Fully Human IgG1 Anti-IL-1β MAb) Induces Sustained Remission in Pediatric Patients with Cryopyrin-associated Periodic Syndrome (CAPS)." Arthritis Research & Therapy, vol. 13, 2011, https://doi.org/10.1186/ar3266.